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AbstrAct
Background and aims: Clinical trials to determine the efficacy of radiotherapy 
(RT) in liver-confined but non-resectable Barcelona Clinic Liver Cancer (BCLC) stage 
C hepatocellular carcinoma (HCC) are scarce. We aimed to determine the benefit of 
RT in such tumors and investigated large HCC tumors.
Methods: HCC data from the Korea Central Cancer Registry recorded from 2008 
to 2010 were used. A total of 593 patients met our inclusion criteria; 67 were treated 
with RT while the remainder made up the non-RT group. Fifty-two RT recipients 
underwent combination treatments within 4 weeks after the first RT treatment, and 
were defined as the combination RT group. We performed propensity score matching 
(PSM) to compare the RT or combination RT groups with the non-RT group. The 
endpoint was overall survival (OS). 
Results: Median follow-up time for surviving patients was 48 months. After PSM, 
there was no difference in OS between the RT and non-RT groups or between the 
combination RT and non-RT groups. However, the combination RT group had a longer 
median survival time (MST) (10.7 vs. 6.9 months, respectively). Next, we conducted 
PSM between the combination RT and non-RT groups in patients with tumor sizes 
≥10 cm; MST was significantly longer in the former group (10.1 vs. 5.4 months, 
respectively; bootstrap 95% confidence interval of the difference in MST: 0.2-11.8). 
Conclusions: As a combined modality, RT is a plausible therapeutic option for 
liver-confined but non-resectable BCLC stage C large HCC patients.
IntroductIon
Currently, the Barcelona Clinic Liver Cancer 
(BCLC) staging system serves as a major treatment 
guideline [1]. BCLC stage C (advanced stage) 
hepatocellular carcinoma (HCC) is highly aggressive, and 
has a dismal survival rate despite the clinical introduction 
of sorafenib, a multi-tyrosine kinase inhibitor [2, 3]. BCLC 
stage C HCC is very heterogeneous, and shows diverse 
patterns ranging from liver-confined HCC with portal 
vein tumor thrombosis to extrahepatic disseminated HCC. 
Due to the aggressiveness and heterogeneity of BCLC 
stage C HCC, sub-classification and optimal therapeutic 
approaches require further investigation. 
The multimodal approach is a basic oncologic 
principle that has been successful in most types of 
locally advanced cancers. It often involves performing 
chemotherapy and radiotherapy, followed by surgery if 
possible [4-6]. Some researchers have examined whether 
the inclusion of RT in the multimodal approach enhances 
the survival outcome for BCLC stage C HCC [7-9], and 
the optimal criteria for local RT have also been evaluated 
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[10, 11]. However, clinical trials for high-level evidence to 
establish the benefit of additional local RT for BCLC stage 
C HCC are still lacking. 
We recently reported that hepatic arterial infusion 
concurrent chemoradiotherapy could improve survival 
for patients with locally advanced HCC with good 
performance and normal liver function when comparing 
our institution’s database to that of the Korean Liver 
Cancer Study Group (KLCSG) nationwide multicenter 
HCC cohort treated between 2003 and 2005 [9]. However, 
this retrospective study compared two independent 
databases with different treatment periods. Furthermore, 
patients who underwent sorafenib treatment were not 
included because the KLCSG database was constructed 
before the sorafenib era. Therefore, additional studies are 
required to confirm our previous finding.
In this study, we investigated the efficacy of 
RT, as well as combination therapy involving RT, in 
comparison to other treatments for liver-confined but 
non-resectable BCLC stage C HCC using a nationwide 
database constructed from a multi-center HCC cohort 
that was based on the Korea Central Cancer Registry. We 
also ascertained the survival benefit of RT in bulky liver-
confined but non-resectable BCLC stage C HCC. 
results
Patient characteristics and survival analysis 
before PsM
The characteristics of all the enrolled patients before 
propensity score matching (PSM) are listed in Table 1. 
There was a significant difference in performance status 
(PS), portal vein (PV) invasion, age, tumor size, and 
α-fetoprotein (AFP) levels between the 2 groups. The 
median ages of patients in the RT and non-RT groups were 
51 (26−83) and 57 (8-98) years, respectively (P = 0.001). 
The RT group had significantly better PS than the non-
RT group; however, the RT group exhibited significantly 
worse prognostic factors than the non-RT group, including 
larger tumor size, higher AFP levels, and greater PV 
invasion. The Child Pugh score was not statistically 
different between the RT and non-RT groups, although 
Figure 1: overall survival before propensity score matching. The Kaplan-Meier survival curve shows that the non-radiotherapy 
(RT) group showed significantly longer overall survival than the RT group (median survival time 12.3 vs. 8.4 months, P = 0.001).
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there was marginal significance (P = 0.077). 
Median follow-up time for surviving patients was 48 
months (range, 36.6-72.5 months). Before PSM, Kaplan-
Meier analyses demonstrated that the non-RT group 
exhibited significantly longer overall survival (OS) than 
the RT group (median survival time [MST] 12.3 vs. 8.4 
months respectively, P = 0.001, Figure 1). Because the 
RT group showed more adverse prognostic factors than 
the non-RT group, we performed PSM analysis to adjust 
for the significant differences in baseline characteristics 
between the 2 groups.
rt versus non-rt group outcomes after PsM
After PSM between the RT (n = 67) and non-RT (n 
= 526) groups, all clinical factors were evenly distributed 
table 1: baseline characteristics for whole cohort
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between each group (Table 1). Survival curves indicated 
that the MST of the RT group was not significantly 
different from that of the non-RT group (8.4 vs. 8.4 
months, hazard ratio [HR] 1.34, 95% confidence interval 
(CI) 0.94-1.91, P = 0.11, Figure 2). 
combination rt versus non-rt groups after PsM 
analysis
As described above, the RT group included patients 
who underwent RT alone (n = 15) and in combination 
with other treatments n = 52). We compared the OS in 
the RT alone, combination RT, and non-RT groups before 
table 2: baseline characteristics between combination rt and non-rt groups for whole cohort
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PSM. Figure 3 shows that the non-RT and combination 
RT groups had significantly longer MSTs than the RT 
alone group (12.3 vs. 10.2 vs. 4.6 months, respectively; 
P = 0.0002). Thus, we performed a second PSM analysis 
between the combination RT and non-RT groups to verify 
the effect of RT when combined with other treatments 
(Table 2). Before PSM analysis, there was a significant 
difference in PS, PV invasion, age, tumor size, Child 
Pugh score, and Child Pugh classification between the 2 
groups. After PSM analysis using covariates that showed 
substantial differences between the combination RT and 
non-RT groups, all clinical factors were distributed evenly. 
In this case, the survival outcomes of the combination 
RT and non-RT groups were not significantly different, 
although the former group had a longer MST (10.7 vs. 6.9 
months, respectively; HR 1.01, 95% CI 0.65-1.55, P = 
0.98, Figure 4).
Table 3: Baseline characteristics between combination RT and non-RT groups in subgroup of tumor size ≥ 10 cm
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Figure 2: Median survival time after propensity score matching: radiotherapy vs. non-radiotherapy groups. The Kaplan-
Meier survival curve in the entire cohort shows that the median survival time (MST) of the radiotherapy (RT) group (8.4 months) was not 
significantly different from that of non-RT group (8.4 months; hazard ratio 1.34, 95% confidence interval 0.94-1.91, P = 0.11).
Figure 3: difference of survival outcome between patients who underwent combination radiotherapy (rt) and rt 
alone. The non-RT and combination RT groups had significantly longer median survival times (MST) than the RT-alone group (12.3 vs. 
10.2 vs. 4.6 months, respectively, P = 0.0002).
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Figure 4: Median survival time after propensity score matching: combination radiotherapy vs. non-radiotherapy groups. 
The survival outcomes in the combination radiotherapy (RT) and non-RT groups were not statistically different, although the combination 
RT group had a longer median survival time (MST) (10.7 vs. 6.9 months respectively, hazard ratio 1.01, 95% confidence interval 0.65-1.55, 
P = 0.98).
Figure 5: Median survival time after propensity score matching: combination radiotherapy vs. non-radiotherapy groups 
in the subset of patients with tumor sizes ≥10 cm. There was a significant difference in median survival time (MST) between the 2 groups 
(10.1 vs. 5.4 months, bootstrap 95% confidence interval [CI] of difference in MST, 0.2-11.8). The combination RT group achieved better 
overall survival despite no statistical significance (hazard ratio 0.69, 95% CI 0.4-1.19, P = 0.17).
Oncotarget62722www.impactjournals.com/oncotarget
os in combination rt versus non-rt groups after 
PSM analysis in patients with tumor sizes ≥10 cm
Subsequently, we performed PSM between the 
patients in the combination RT and non-RT groups with 
tumor sizes ≥10 cm (n = 31 and n = 169, respectively) to 
identify the survival benefit of RT in liver-confined bulky 
non-resectable tumors. There was a significant difference 
in age and tumor size between the 2 groups before PSM 
(Table 3). PV invasion and HCC etiology were also 
significantly different between the groups (P = 0.072 and 
P = 0.06, respectively). Thus, we performed PSM via 
logistic regression using age, tumor size, PV invasion, and 
HCC etiology; all patient characteristics were balanced 
after PSM analysis. On survival analysis after PSM, we 
observed a significant difference in MST between the 
2 groups (10.1 vs. 5.4 months respectively, bootstrap 
95% CI of difference in MST, 0.2-11.8; Figure 5). The 
combination RT group achieved better OS, although the 
difference was not statistically significant (HR 0.69, 95% 
CI 0.4-1.19, P = 0.17; Figure 5).
dIscussIon
This nationwide retrospective cohort study utilizing 
PSM analysis demonstrated that there was no significant 
difference in OS between the RT and non-RT groups for 
liver-confined but non-resectable BCLC stage C HCC 
patients. Furthermore, the OS was not significantly 
different when comparing the combination RT to the 
non-RT groups after PSM. However, the combination RT 
group exhibited longer MST, although without statistical 
significance. Additionally, we performed PSM between 
combination RT and non-RT subgroups for patients with 
tumor sizes ≥10 cm. We found that the combination RT 
group exhibited significantly improved MST compared 
to the non-RT group in the subset of patients with larger 
tumors, and that the combination RT group achieved 
better OS (although the improvement was not statistically 
significant).
Our findings are subject to certain limitations; for 
example, this study was retrospective, and the number of 
patients included in the RT group was small. The patients 
were heterogeneous and the proper descriptions of RT 
modality, total doses and fractionations were lacking. 
Furthermore, there is no data regarding clinical events 
and toxicity available through our database. Despite these 
drawbacks, this study is the first to use a single nationwide 
multi-center cohort to investigate the survival benefit of 
RT in liver-confined but non-resectable BCLC stage 
C HCC patients. Additionally, there was a significant 
difference in MST between the combination RT and non-
RT groups in the subset of patients with bulky tumors. 
Large-size HCCs are known to have higher AFP 
levels, higher rates of microscopic and macroscopic 
vascular invasion, more advanced stages, and rupturing 
compared to small HCCs [17, 18]. The prognosis of this 
disease is dismal, with a 5-year disease-free survival rate 
of 12.7-38.6% and a 5-year OS rate of 16.7-40.2% despite 
radical resection [17-21]. However, resectable cases do not 
account for an appreciable portion of large HCC patients 
[10]. Several types of treatments have been performed for 
huge HCC, including trans-arterial therapy, chemotherapy, 
and RT [22-25]. Recent studies have demonstrated that 
combining RT with other treatments, such as trans-arterial 
therapy or hepatic arterial infusion chemotherapy (HAIC), 
is effective for large HCC [25-27]. Kim et al. reported that 
RT with concurrent HAIC (HAICCRT) followed by HAIC 
or RT plus TACE resulted in excellent intrahepatic control 
and improvement of survival (MST: 12.8 months for 
HAICCRT and 15.3 months for RT plus TACE) for non-
resectable very large HCCs [25]. Zhong et al. investigated 
the safety and efficacy of stereotactic body radiotherapy 
combined with TACE for large HCC and reported 
excellent therapeutic outcomes, with an objective response 
rate of 79.1% and MST of 12.2 months [26]. Similar to 
the results of previous studies, our findings indicate that 
RT combined with another treatment, particularly trans-
arterial therapy, could enhance survival. These findings 
indicate the clinical benefit of choosing RT for large non-
resectable HCC as the preferred treatment. In principle, a 
prospective randomized clinical trial is required to verify 
our findings regarding the survival benefit of additional RT 
for large non-resectable HCC. 
Our findings demonstrated that the combination 
RT group achieved better OS in patients with tumor sizes 
≥10 cm, although the improvement was not significant. 
Generally, MST may be more appropriate for evaluating 
treatment outcomes of patients with poor prognoses. 
Indeed, significantly longer MST was demonstrated in the 
combination RT group than in the non-RT group in this 
study. 
In conclusion, this nationwide retrospective cohort 
study demonstrates that the addition of RT to other 
treatments is associated significantly with improvement 
of MST for large HCCs by approximately 5 months. RT 
as a combined modality can be considered a therapeutic 
option for liver-confined but non-resectable BCLC stage 
C large HCC patients. 
Methods And MAterIAls
Multi-center hepatocellular carcinoma cohort
HCC data from the Korea Central Cancer Registry 
were used to perform the systemic randomized sampling. 
This database was based on information collected from 
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47 institutions in Korea; patients enrolled in this database 
underwent treatment for HCC between 2008 and 2010. 
This database included information on age; sex; PS; 
smoking history; pack years; tumor size; AFP levels; 
Child-Pugh class or score; number of tumor masses; 
nodal metastasis; PV, hepatic vein, bile duct, and hepatic 
artery invasion; HCC etiology; and survival. Staging was 
determined according to the BCLC staging system [1]. 
HCC was diagnosed according to the practice guidelines 
for diagnosis and treatment of HCC of the KLCSG [12, 
13]. HCC was defined as pathologic confirmation of HCC 
or compatible radiological findings with the elevation of 
serum AFP level ( > 400 IU/mL before 2009 or > 200 IU/
mL after 2009) [12, 13]. If AFP levels were lower than 
the cut-off values (i.e., ≤400 IU/mL before 2009 or ≤200 
IU/mL after 2009), HCC was diagnosed by radiological 
findings using at least two imaging modalities [12, 13]. 
Patient selection and groups
There were 4596 patients in total; inclusion criteria 
were liver-confined, non-resectable BCLC stage C HCC. 
We excluded patients according to the following criteria: 
1) BCLC stages A, B, and D; 2) distant metastasis; 3) 
patients who underwent surgery as the first treatment or 
had no treatment; or 4) missing clinical factor information. 
Ultimately, 593 patients were included in this study. Sixty-
seven patients were treated with RT and defined as the RT 
group. The remaining patients were considered the non-RT 
group. In the RT group, 52 (77.6%) patients underwent 
combination treatments involving other modalities within 
4 weeks after the initial treatment; these patients were 
defined as the combination RT group. 
treatments
RT, sorafenib, systemic chemotherapy, trans-arterial 
therapy, and local ablation therapy were performed on 
patients in this study. Trans-arterial therapy included 
trans-arterial chemoembolization (TACE) with gelform, 
trans-arterial chemolipiodolization without gelform, trans-
arterial therapy without gelform or lipiodol, TACE with 
beads, and radioembolization. The information regarding 
regimens for systemic chemotherapy was not available in 
the database; however, we expect that most patients in this 
study were treated with systemic chemotherapy regimens 
according to the KLCSG practice guidelines for diagnosis 
and treatment of HCC [12, 13]. Local ablation therapy 
consisted of radiofrequency ablation, ethanol ablation, 
and other ablation therapies. For the 52 combination RT 
patients, the other therapies included sorafenib, systemic 
chemotherapy, and trans-arterial therapy in 13, 2, and 
37 patients, respectively. In the non-RT group, local 
ablation therapy was administered to 34 patients (6.5%), 
trans-arterial therapy to 444 patients (84.4%), systemic 
chemotherapy to 32 patients (6.1%), and sorafenib to 16 
patients (3.0%). 
study design
The study was performed and reported in accordance 
with the recommendations of the Strengthening the 
Reporting of Observational Studies in Epidemiology 
statement [14]. This study was approved by the internal 
review boards at Severance hospital (IRB no. 4-2015-
1157). First, we compared the baseline characteristics 
between the treatment groups to evaluate the differences in 
confounding covariates. Next, we performed PSM analysis 
to adjustment for variables that showed statistically 
significant differences, and then analyzed the survival 
difference between treatment groups. 
statistical analysis
The primary endpoint was OS, which was defined 
as the period between the treatment start date and the 
date of death or last follow-up. Before PSM analysis, 
OS for all patients included in this study was calculated 
using the Kaplan-Meier method and compared between 
the RT and non-RT groups using the log-rank test. To 
minimize potential confounding effects of covariates and 
selection bias, we utilized PSM analysis for data balancing 
between groups [15]. For assessment of the difference 
in potential confounders between the RT and non-RT 
groups, we performed Pearson’s χ2 test or Fisher’s exact 
test to compare differences in nominal variables in patient 
characteristics; differences in continuous variables were 
analyzed using the Mann-Whitney U test. 
We performed 1 to 1 ratio PSM analysis thrice 
to compare 1) the RT group to the non-RT group, 2) 
the combination RT group to the non-RT group, and 
3) the combination RT group to the non-RT group in 
the subset of patients with tumor sizes ≥10 cm. After 
performing each PSM analysis, we compared the baseline 
characteristics between the 2 groups by using conditional 
logistic regression. For survival analysis after PSM, we 
performed Cox regression model analyses to compare 
the risks of outcome in each group using robust standard 
errors that considered the clustering of matched pairs. We 
graphed survival curves using Kaplan-Meier estimates, 
and compared the OS of treatment groups using the 
methods devised by Klein and Moeschberger [16]. 
All statistical analyses were 2-sided. P values ≤0.05 
were considered statistically significant. All statistical 
analyses were conducted using the SAS software, version 
9.2.
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